COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey

Lamure, Sylvain; Salmanton‐García, Jon; MARIETON, Elena ROBIN; Jakšić, Ozren; Kohn, Milena; Marchesi, Francesco; Marchetti, Monia; El-Ashwah, Shaimaa; Demırkan, Fatih; Valković, Toni; Escalada, Noemi Fernández; Tisi, Maria Chiara; Stojanoski, Zlate; Seval, Güldane Cengiz; İlhan, Osman; Prezioso, Lucia; Merelli, Maria; López‐García, Alberto; Ledoux, Marie‐Pierre; Kulasekararaj, Austin; González-López, Tomás José; Silva, Maria Gomes da; Emarah, Ziad; Duarte, Rafael F.; Cattaneo, Chiara; Blennow, Ola; Bilgin, Yavuz M.; Bergantim, Rui; Batinić, Josip; Córdoba, Raúl; Essame, Jenna; Nordlander, Anna; Rodrigues, Raquel Nunes; Sacchi, Maria Vittoria; Zompi, Sofia; Busca, Alessandro; Corradini, Paolo; Hoenigl, Martin; Климко, Н Н; Köehler, Philipp; Pagliuca, Antonio; Passamonti, Francesco; Duléry, Rémy; Cornely, Oliver A.; Besson, Caroline; Pagano, Livio

doi:10.1182/bloodadvances.2022007357

Cited by 8 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whereas the associations we observed in HCL between COVID‐19 course and clinical variables like age, comorbidities and disease status are broadly similar to those observed in other haematological malignancies, 3 , 5 , 6 including chronic lymphocytic leukaemia (CLL), 7 the HCL cohort reported by Lamure et al 2 showed, compared to ours, higher rates of non‐mild COVID‐19 (83%, 33/40 patients, including five previously vaccinated) and death (29%; 10/35 cases), despite a median age (60 years) and comorbidity rate (33%) similar to ours (58 years and 35%, respectively). Reasons underlying this discrepancy might include: shorter time from HCL diagnosis to COVID‐19 in their cohort (median 14 months, 2 vs. 92 in ours); likely shorter time from last anti‐leukaemic treatment in their series (median 3 months in the only 13/40 patients with these data 2 ) versus ours (median 29 months); and fewer patients in remission or with untreated stable disease in their versus our cohort (respectively 26/40, 65% 2 ; and 28/37, 76%).…”

Section: Methodssupporting

confidence: 87%

“…Little is known about COVID‐19 outcome in HCL patients and on their antibody response to infection or vaccination. In particular, the only published cohort study focusing on HCL ( n = 40 patients) recently reported a largely severe (48% of cases) or critical (35%) disease course, with 10 deaths (including nine COVID‐19‐related) in 35 unvaccinated cases (29%) and none in five vaccinated patients 2 . Herein, we describe a larger HCL cohort (58 patients in total) not only for COVID‐19 outcome in unvaccinated and vaccinated cases, but also for seroconversion post infection and post vaccination.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

SARS‐CoV‐2 infection and vaccination in patients with hairy‐cell leukaemia

Tiacci¹,

Mancini²,

Marchetti

et al. 2022

Br J Haematol

Self Cite

View full text Add to dashboard Cite

Summary Little is known of the course of COVID‐19 and the antibody response to infection or vaccination in patients with hairy‐cell leukaemia (HCL). Among a total of 58 HCL cases we studied in these regards, 37 unvaccinated patients, mostly enjoying a relatively long period free from anti‐leukaemic treatment, developed COVID‐19 between March 2020 and December 2021 with a usually favourable outcome (fatality rate: 5/37, 14%); however, active leukaemia, older age and more comorbidities were associated with a worse course. Postinfection ( n = 11 cases) and postvaccination ( n = 28) seroconversion consistently developed, except after recent anti‐CD20 or venetoclax therapy, correlating with perivaccine B‐cell count. Vaccination appeared to protect from severe COVID‐19 in 11 patients with breakthrough infection.

show abstract

Section: Methodssupporting

confidence: 87%

Section: Introductionmentioning

confidence: 99%

SARS‐CoV‐2 infection and vaccination in patients with hairy‐cell leukaemia

Tiacci¹,

Mancini²,

Marchetti

et al. 2022

Br J Haematol

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, to date, few data are available about the impact of starting early versus delayed specific HM treatment as well as the outcome of patients with simultaneous onset of HM and COVID-19. Some recommendations from expert panels have raised concern regarding the management of specific HM, including acute leukaemia (AL), multiple myeloma (MM) and hairy cell leukaemia (HCL), during the pandemic [ 4 , 5 , 6 , 7 , 8 ]. In these recommendations, few suggestions apply to patients with simultaneous HM and COVID-19 diagnosis, and the advice is usually to delay, when possible, the start of HM therapy.…”

Section: Introductionmentioning

confidence: 99%

Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

Cattaneo

Salmanton‐García

Marchesi

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.

show abstract

“…Four out of the five patients were previously treated for HCL, two of them during the last year. The median time from infection to hospitalization was 9 days 2–12 …”

Section: Resultsmentioning

confidence: 99%

“…Only one study reported the outcome of a cohort of patients with HCL until 26 January 2022, during the Covid‐19 pandemic: the EPICOVIDEHA survey 12 . In a letter to the editor, they reported the results of a survey on the outcome of 40 patients with HCL and Covid‐19 infection.…”

Section: Discussionmentioning

confidence: 99%

The course of patients with hairy cell leukemia during the omicron surge of the Covid‐19 pandemic

Tadmor

Melamed

Patalon

et al. 2023

Hematological Oncology

View full text Add to dashboard Cite

In this study, we aim to explore the outcomes of Covid‐19 infection in patients with Hairy cell leukemia (HCL). The cohort is based on data obtained from electronic medical records. It includes 218 consecutive patients diagnosed with HCL between 16 June 1998, and 20 September 2022, out of which the coronavirus has infected 85 patients during the Omicron surge. Out of 85 patients with HCL who were infected by Covid‐19; 7 patients (8.2%) have been hospitalized, and the mortality rate was 2.3% (two patients). Thirteen of the 85 patients had been infected by Covid‐19 in previous waves, including 9/13 after vaccination, and none of them developed a severe disease. Humoral immune response after three doses of the BNT162b2 mRNA vaccination regimen was evaluated in 40 patients and was attained in 67.5%. Based on multivariate analysis: unfavorable outcome was significantly more common in patients with HCL above 65 years old, who had at least one cytopenia, and with comorbidity of cardiovascular disease or asplenia. Our results indicates that the course of COVID‐19 in patients with HCL during the Omicron wave has been improved relatively favorable.

show abstract

COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey

Cited by 8 publications

References 17 publications

SARS‐CoV‐2 infection and vaccination in patients with hairy‐cell leukaemia

SARS‐CoV‐2 infection and vaccination in patients with hairy‐cell leukaemia

Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

The course of patients with hairy cell leukemia during the omicron surge of the Covid‐19 pandemic

Contact Info

Product

Resources

About